Published in Cancer Weekly, October 7th, 1996
The results showed that treatment with Maxamine therapy continues to extend the duration of remission well beyond the length of remission reported for patients in previously published AML trials using interleukin-2 (IL-2). In addition, four patients have discontinued therapy given the extended duration of their remission and their physician's suggestion that they may have a low probability of relapse.
Based on the data generated to date, Maxim is adding patients and clinical trial sites in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.